Table 1 LCN2 protein expression by various clinico-pathological variables and molecular markers among 256 endometrial cancers
From: Lipocalin 2 expression is associated with aggressive features of endometrial cancer
Variable | LCN2 SI 0N (%) | LCN2 SI 1-9N (%) | P-valuea | |
|---|---|---|---|---|
Histologic type | Endometrioid | 126 (55%) | 103 (45%) | 0.001 |
Non- endometrioid | 5 (19%) | 22 (81%) | ||
Histologic grade | Grade 1 and 2 | 89 (56%) | 71 (44%) | 0.066 |
Grade 3 | 42 (44%) | 54 (56%) | ||
Nuclear grade | Grade 1 and 2 | 101 (59%) | 71 (41%) | 0.001 |
Grade 3 | 30 (36%) | 54 (64%) | ||
Solid growth | <50% | 104 (56%) | 82 (44%) | 0.013 |
≥50% | 27 (39%) | 43 (61%) | ||
Mitosesb | Low | 103 (54%) | 89 (46%) | NS |
High | 28 (44%) | 36 (56%) | ||
FIGO stagec,d | I/II | 109 (53%) | 97 (47%) | NS |
III/IV | 22 (45%) | 27 (55%) | ||
ERe,f | Negative | 25 (40%) | 38 (60%) | 0.028 |
Positive | 103 (56%) | 82 (44%) | ||
PRg,h | Negative | 28 (38%) | 46 (62%) | 0.006 |
Positive | 98 (57%) | 74 (43%) | ||
EZH2i,j | Weak | 121 (56%) | 94 (44%) | <0.001 |
Strong | 10 (24%) | 31 (76%) | ||
HER2k,l | Weak | 115 (54%) | 100 (46%) | 0.084 |
Strong | 11 (37%) | 19 (63%) | ||
VEGF-Am,n | Weak | 114 (55%) | 94 (45%) | 0.021 |
Strong | 17 (36%) | 30 (64%) |